9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 141

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: To establish the maximally tolerated dose (MTD) of intraoperative Intrathoracic/Intraperitoneal hyperthermic gemcitabine and cisplatin combination modulated by amifostine and sodium thiosulfate in patients with malignant pleural mesothelioma.,  To determine and quantitate the safety of this combination in these patients by defining the dose limiting toxicity.,  To study the pharmacokinetics of gemcitabine and cisplatin combination administered in this way.,

Interventions: Extrapleural pneumonectomy (EPP), Cisplatin

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: November 2011

Completion Date: June 2015

Last  Posted Date: January 23, 2017

Location: Brigham and Women’s Hospital, Boston, Massachusetts, United States

Website Link: https://ClinicalTrials.gov/show/NCT00571298

Was this article helpful?
Dislike 0